LncRNA LINC00663对胶质瘤细胞增殖及凋亡的影响  

Effects of LncRNA LINC00663 on Proliferation and Apoptosis of Human Glioma Cells

作　　者：时景仁 郭晶晶[1] 王爽 王雅杰 SHI Jingren;GUO Jingjing;WANG Shuang;WANG Yajie(Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China)

机构地区：[1]首都医科大学附属北京地坛医院检验科,北京100015

出　　处：《标记免疫分析与临床》2022年第11期1916-1920,1951,共6页Labeled Immunoassays and Clinical Medicine

基　　金：国家自然科学基金(编号:81572474)。

摘　　要：目的探讨长链非编码RNA(LncRNA)-LINC00663对胶质瘤细胞增殖和凋亡的影响,并探讨其可能机制。方法实时荧光定量PCR检测人脐静脉内皮细胞(HUVEC)和胶质瘤细胞系A172中LINC00663的表达水平。用siRNA沉默A172细胞中LINC00663的表达,分为siRNA-NC组和siRNA-LINC组,采用CCK-8法和EDU法检测细胞增殖,流式细胞术AnnexinV-FITC/7-AAD双染法检测细胞凋亡率,Western blot检测凋亡相关蛋白Bax和Bcl-2的表达水平,Western blot检测细胞内Wnt3a表达水平。结果A172细胞中LINC00663的表达水平明显高于HUVEC(P<0.01)。与siRNA-NC组相比,siRNA-LINC组细胞增殖能力降低,凋亡率增加,Wnt3a表达水平降低,差异具有统计学意义(P<0.05)。结论LINC00663可能通过调控Wnt3a表达影响A172细胞的增殖和凋亡。Objective To investigate the effects of long non-coding RNA(LncRNA)-LINC00663 on proliferation and apoptosis in human glioma cell line A172 and the underlying molecular mechanism.Methods The expression of LINC00663 in human umbilical vein endothelial cell line HUVEC and human glioma cell line A172 was determined by real-time fluorescence quantitative PCR.The expression of LINC00663 in A172 cells was silenced by siRNA,then cells were divided in the siRNA-NC group and siRNA-LINC group.Cell counting Kit-8 and EdU assay were adopted for the analysis of cell proliferation.Cell apoptosis were evaluated by flow cytometry.The expression levels of BAX,BCL-2,and Wnt3a were determined by western blotting.Results The expression level of LINC00663 in A172 cells was significantly higher than that in HUVEC(P<0.01).Compared with the siRNA-NC group,the expression level of LINC00663,the cell proliferation ability,and the expression level of Wnt3a in the siRNA-LINC group were decreased,while the apoptotic rate of cells increased significantly(P<0.05).Conclusion LINC00663 may affect the proliferation and apoptosis of A172 cells by regulating the expression of Wnt3a.

关 键 词：胶质瘤 LINC00663 增殖 凋亡 WNT3A 

分 类 号：R739.41[医药卫生—肿瘤]